Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Research Suggests That Diosmin Can Help Improve Diabetic Vascular Conditions
French research on Daflon 500 mg taken daily (90% of which is comprised of the supplement Diosmin), indicates 12 of 13 patients in one study showed normalization of albumin levels in the urine after treatment, second study (placebo controlled, 20 patients in each group) indicated that in 65% of supplementation group, albumin levels normalized, compared to only 25% of patients in the placebo group.
- Research Suggests That Diosmin Can Help Improve Diabetic Vascular Conditions
French research on Daflon 500 mg taken daily (90% of which is comprised of the supplement Diosmin), indicates 12 of 13 patients in one study showed normalization of albumin levels in the urine after treatment, second study (placebo controlled, 20 patients in each group) indicated that in 65% of supplementation group, albumin levels normalized, compared to only 25% of patients in the placebo group.
- Research Suggests That Diosmin Can Help Improve Diabetic Vascular Conditions
French research on Daflon 500 mg taken daily (90% of which is comprised of the supplement Diosmin), indicates 12 of 13 patients in one study showed normalization of albumin levels in the urine after treatment, second study (placebo controlled, 20 patients in each group) indicated that in 65% of supplementation group, albumin levels normalized, compared to only 25% of patients in the placebo group.
- Research Suggests That Diosmin Can Help Improve Diabetic Vascular Conditions
French research on Daflon 500 mg taken daily (90% of which is comprised of the supplement Diosmin), indicates 12 of 13 patients in one study showed normalization of albumin levels in the urine after treatment, second study (placebo controlled, 20 patients in each group) indicated that in 65% of supplementation group, albumin levels normalized, compared to only 25% of patients in the placebo group.
- Carlson Fish Oil Prescribed In Landmark BARI 2D Trial
The American Journal of Cardiology June 19, 2006 volume published preliminary information regarding the landmark Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial, investigating the effects of intervention factors such as pharmaceutical drugs or nonpharmacologic interventions such as fish oils on patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Carlson Laboratories is supplying fish oil to study participants.
- Carlson Fish Oil Prescribed In Landmark BARI 2D Trial
The American Journal of Cardiology June 19, 2006 volume published preliminary information regarding the landmark Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial, investigating the effects of intervention factors such as pharmaceutical drugs or nonpharmacologic interventions such as fish oils on patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Carlson Laboratories is supplying fish oil to study participants.
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients
A recent clinical trial wherein supplementary fish oil
containing omega-3 fatty acids was given to patients for a median time of
3 weeks (up to 7 weeks) prior to surgical removal of their advanced
carotid atherosclerotic plaques
- NMI Introduces New LOHAS Consumer Panel
The Natural Marketing Institute (NMI) is helping companies to capitalize on the LOHAS momentum by analyzing LOHAS consumers as predictors of upcoming trends.
- NMI Introduces New LOHAS Consumer Panel
The Natural Marketing Institute (NMI) is helping companies to capitalize on the LOHAS momentum by analyzing LOHAS consumers as predictors of upcoming trends.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity
Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls).
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Presenter: Alison Hill at the 2006 ISSFAL Meeting in Cairns, Australia
Institution: Nutritional Physiology Research Centre, University of South Australia and University of Adelaide, Australia
Allison Hill reported this morning, at the ISSFAL (International Society for the Study of Fatty Acids & Lipids) Congress in Cairns, Australia, new research findings on adjunct supplementation with fish oil in obese or overweight subjects (25 – 65 years old) assigned to a regular exercise regimen. At entry, the 75 men and women, who also had two cardiovascular disease risk factors such as hypertension, elevated blood cholesterol or triglyceride, participated in a double – blind trial of 12 weeks in duration.
The participants were assigned to either daily supplementation with vegetable oil with or without an exercise regimen or daily fish oil supplementation (providing 2 grams of DHA/EPA omega-3 fatty acids) with orwithout exercise. The moderate exercise program as assigned to half the subjects consisted of three running sessions per week for 45 minutes each at 75% of their age-predicted maximum heart rate.
Body compositions as increased by Dual Energy X-ray Absorptiometry revealed that the only group to exhibit a significant reduction in % body fat was that combining exercise with fish oil supplementation. This improvement appeared to reflect an enhanced fat oxidation during exercise.
The fish oil plus exercise regimen also gave a lessened surge in the heart rate rise with exercise which was attributed to a reduced vascular resistance and an improved blood flow in exercising muscles.
This novel research indicates the potential for fish oil supplementation to enhance the efficacy of exercise programs in overweight subjects.
More information: www.dhaomega3.org |